AnaptysBio Inc (ANAB)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Employees:
78
10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO, CA 92121
858-362-6295

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.

Data derived from most recent annual or quarterly report
Market Cap 783.222 Million Shares Outstanding27.433 Million Avg 30-day Volume 144.085 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 35.85 / 17.72 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from ANAB instead.

View recent insider trading info

Funds Holding ANAB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ANAB BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

10 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SURIA HAMZA PRESIDENT, CEO

  • Officer
  • Director
87,997 2021-09-17 3

ECOR1 CAPITAL, LLC

NODELMAN OLEG

  • Director
  • 10% Owner
7,520,424 2021-04-30 3

NODELMAN OLEG

  • Director
  • 10% Owner
7,151,624 2021-04-08 3

ECOR1 CAPITAL, LLC

  • 10% Owner
7,151,624 2021-03-08 3

FENTON DENNIS M

  • Director
0 2021-02-10 1

RENTON HOLLINGS

  • Director
0 2021-02-10 1

LOUMEAU ERIC J COO, GENERAL COUNSEL

  • Officer
0 2021-02-10 1

MULROY DENNIS CHIEF FINANCIAL OFFICER

  • Officer
0 2021-02-10 1

TOPPER JAMES N

  • Director
  • 10% Owner
0 2021-02-10 2

SCHMID JOHN P.

  • Director
0 2021-02-10 1

MARQUET MAGDA

  • Director
0 2021-02-10 3

LIZZUL PAUL F. CHIEF MEDICAL OFFICER

  • Officer
0 2021-02-10 1

WARE J. ANTHONY

  • Director
0 2021-02-10 1

HAMILL LAURA

  • Director
0 2021-02-10 1

LONDEI MARCO CHIEF MEDICAL OFFICER

  • Officer
0 2019-12-06 0

LYDON NICHOLAS

  • Director
0 2019-02-08 0

PISCITELLI DOMINIC CHIEF FINANCIAL OFFICER

  • Officer
0 2019-02-08 0

FRAZIER HEALTHCARE V, LP

FHM V, LP

FHM V, LLC

FRAZIER ALAN D

NAINI NADER J

EVERY NATHAN R

HERON PATRICK J

  • 10% Owner
No longer subject to file 2018-05-11 0

FRAZIER HEALTHCARE VII, L.P.

FRAZIER HEALTHCARE VII-A, L.P.

FHM VII, L.P.

FHM VII, L.L.C.

FRAZIER ALAN D

NAINI NADER J

EVERY NATHAN R

HERON PATRICK J

  • 10% Owner
No longer subject to file 2018-05-11 0

GALLAGHER CAROL GILTNER

  • Director
0 2018-02-02 0

SCHOENECK JAMES A

  • Director
0 2018-02-02 0

NOVO HOLDINGS A/S

  • 10% Owner
No longer subject to file 2017-08-21 0

AVALON VENTURES VII L P

AVALON VENTURES VII GP, LLC

KINSELLA KEVIN J

TOMLIN STEPHEN LAWRENCE

  • 10% Owner
  • SEE REMARKSSEE REMARKSSEE REMARKS
No longer subject to file 2017-07-26 0

MOYLE MATTHEW CHIEF SCIENTIFIC OFFICER

  • Officer
0 2017-02-24 0

AVALON VENTURES VII L P

KINSELLA KEVIN J

TOMLIN STEPHEN LAWRENCE

  • 10% Owner
2,036,932 2017-01-25 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SURIA HAMZA - Director - Officer PRESIDENT, CEO

2021-09-21 17:38:35 -0400 2021-09-17 M 10,000 $1.12 a 67,636 direct -0.0356 -5.5872 0.0 1 -5.5872 6

SURIA HAMZA - Director - Officer PRESIDENT, CEO

2021-09-21 17:38:35 -0400 2021-09-17 M 10,000 d 20,361 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ANAPTYSBIO INC ANAB 2021-10-26 21:15:03 UTC -0.205 0.275 1100000
ANAPTYSBIO INC ANAB 2021-10-26 20:45:03 UTC -0.205 0.275 1100000
ANAPTYSBIO INC ANAB 2021-10-26 20:15:03 UTC -0.205 0.275 1100000
ANAPTYSBIO INC ANAB 2021-10-26 19:45:03 UTC -0.205 0.275 1100000
ANAPTYSBIO INC ANAB 2021-10-26 19:15:03 UTC -0.205 0.275 1100000
ANAPTYSBIO INC ANAB 2021-10-26 18:45:03 UTC -0.205 0.275 1100000
ANAPTYSBIO INC ANAB 2021-10-26 18:15:03 UTC -0.205 0.275 1100000
ANAPTYSBIO INC ANAB 2021-10-26 17:45:03 UTC -0.205 0.275 1100000
ANAPTYSBIO INC ANAB 2021-10-26 17:15:03 UTC -0.205 0.275 1100000
ANAPTYSBIO INC ANAB 2021-10-26 16:45:04 UTC -0.1954 0.2654 1100000
ANAPTYSBIO INC ANAB 2021-10-26 16:15:03 UTC -0.1954 0.2654 1100000
ANAPTYSBIO INC ANAB 2021-10-26 15:45:03 UTC -0.1954 0.2654 1100000
ANAPTYSBIO INC ANAB 2021-10-26 15:15:03 UTC -0.1954 0.2654 1100000
ANAPTYSBIO INC ANAB 2021-10-26 14:45:03 UTC -0.1967 0.2667 1100000
ANAPTYSBIO INC ANAB 2021-10-26 14:15:05 UTC -0.1967 0.2667 1100000
ANAPTYSBIO INC ANAB 2021-10-26 13:45:03 UTC -0.1967 0.2667 1100000
ANAPTYSBIO INC ANAB 2021-10-26 13:15:03 UTC -0.1967 0.2667 1100000
ANAPTYSBIO INC ANAB 2021-10-26 12:45:03 UTC -0.1967 0.2667 1100000
ANAPTYSBIO INC ANAB 2021-10-25 22:15:03 UTC -0.1967 0.2667 1000000
ANAPTYSBIO INC ANAB 2021-10-25 21:45:03 UTC -0.1967 0.2667 1000000

Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin
PDT Partners, LLC AnaptysBio, Inc. 0.59% 2018-02-07 GERMANY

Short Position History (International Only)

Holder Net Short Position Position Date Origin
PDT Partners, LLC AnaptysBio, Inc. 0.68% 2018-01-25 GERMANY
PDT Partners, LLC AnaptysBio, Inc. 0.7% 2018-01-24 GERMANY

Elevate your investments